## CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating webbased and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <a href="http://www.jmir.org/2011/4/e126/">http://www.jmir.org/2011/4/e126/</a>

doi: 10.2196/imir.1923

PMID: 22209829

\* Required

Your name *
First Last
Sarah Mummah
Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
University of Cambridge
Your e-mail address *
abc@gmail.com
sm885@cam.ac.uk
Title of your manuscript *
Provide the (draft) title of your manuscript.
Mobile technology for vegetable consumption: a randomized controlled pilot study in overweight adults
processes, in every significant
Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)
onot submitted yet - in early draft status
o not submitted yet - in late draft status, just before submission
osubmitted to a journal but not reviewed yet
submitted to a journal and after receiving initial reviewer comments
submitted to a journal and accepted, but not published yet
O published
Other:
Lacoura I de
Journal *  If you already know where you will submit this paper (or if it is already submitted), please provide the
journal name (if it is not JMIR, provide the journal name under "other")
not submitted yet / unclear where I will submit this
Journal of Medical Internet Research (JMIR)
- Joanna, or Modical Internet Research (OMIN)
Other:

#### Manuscript tracking number \*

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

ono ms number (yet) / not (yet) submitted to / published in JMIR	
Other:	
TITLE AND ABSTRACT	
1a) TITLE: Identification as a randomized trial in	the title
1a) Does your paper address CONSORT item 1a? * I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the rea "other")	ason under
o yes	
Other:	
1a-i) Identify the mode of delivery in the title  Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electron the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" Intervention includes non-web-based Internet components (e.g. email), use "computer-based" electronic" only if offline products are used. Use "virtual" only in the context of "virtual reworlds). Use "online" only in the context of "online support groups". Complement or substances with broader terms for the class of products (such as "mobile" or "smart phone" in "iphone"), especially if the application runs on different platforms.	only if ased" or ality" (3-D titute product
1 2 3 4 5	
subitem not at all important O O O essential	
Does your paper address subitem 1a-i? * Copy and paste relevant sections from manuscript title (include quotes in quotation mark	
indicate direct quotes from your manuscript), or elaborate on this item by providing addit information not in the ms, or briefly explain why the item is not applicable/relevant for yo "Mobile"	
<b>1a-ii) Non-web-based components or important co-interventions in title</b> Mention non-web-based components or important co-interventions in title, if any (e.g., "w support").	ith telephone
1 2 3 4 5	
subitem not at all important O O O essential	

#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to
indicate direct quotes from your manuscript), or elaborate on this item by providing additional
information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/a			
			/

#### 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5 subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"in overweight adults"		

### 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

#### 1b-i) Key features/functionalities/components of the intervention and comparator in the **METHODS** section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"[Participants were] randomized to the use of Vegethon (a fully automated theory-driven mobile app enabling self-monitoring of vegetable consumption, goal setting, feedback, and social comparison) or a wait-listed control condition."

#### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5 subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"fully automated"

#### 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the **METHODS** section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	$\circ$	0	essential

#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were recruited from an ongoing 12-month weight loss trial (parent trial). Participants and researchers who performed data analysis were blinded to condition assignment. The primary outcome measure was daily vegetable consumption, assessed using an adapted version of the validated Harvard Food Frequency Questionnaire (FFQ) administered at baseline and 12 weeks post-randomization."

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5 subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Using intention-to-treat analyses, all enrolled participants (intervention: 8; control: 9) were analyzed. Of the 8 participants randomized to the intervention, 5 downloaded the app and logged their vegetable consumption a mean of 0.7 (SD=0.9) times per day, 2 downloaded the app but did not use it, and 1 never downloaded it."

"Consumption of vegetables was significantly greater among the intervention vs. control condition at the end of the 12-week pilot study (adjusted mean difference: 7.4 servings; 95% CI: 1.4, 13.5; p=0.02). Among secondary outcomes defined a priori, there was significantly greater consumption of green leafy vegetables, dark yellow vegetables, and cruciferous vegetables (adjusted mean difference: 2.6; 1.6; and 0.8 servings; 95% CI: 0.1, 5.0; 0.1, 3.2; and 0.3, 1.4; p=0.04; 0.04; and 0.004; respectively). "

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is

negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	0	$\bigcirc$	essential

#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/a	
	/

#### INTRODUCTION

### 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	$\circ$	$\circ$	$\circ$	$\circ$	0	essential

#### Does your paper address subitem 2a-i? \*

"Most mobile health apps are yet to undergo evaluation in randomized trials or incorporate theory-based strategies known to drive changes in health behaviors."

"This pilot study (Trial Registration: ClinicalTrials.gov NCT01826591) aimed to assess the initial efficacy and user acceptability of Vegethon, a stand-alone mobile app designed to increase vegetable consumption through the creative application of behavior change theory and techniques. It is among the first apps specifically targeting only vegetable consumption to undergo evaluation in a randomized study of adults attempting to lose weight."

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"An explosion of health-promoting mobile apps has occurred in recent years [22] including apps to promote weight control [23], healthier eating [24-26], and greater vegetable consumption [27]. ... Theory-driven behavior change techniques [31] may form the basis of apps that more effectively produce improvements in health behaviors. Investigators have called for both the theory-informed development and rigorous evaluation of mobile-based interventions [32, 33]. With the mobile health (mHealth) field still in its infancy, it is likely that the most effective approaches are yet to be explored."

# 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

"This pilot study (Trial Registration: ClinicalTrials.gov NCT01826591) aimed to assess the initial efficacy and user acceptability of Vegethon, a stand-alone mobile app designed to increase vegetable consumption through the creative application of behavior change theory and techniques. It is among the first apps specifically targeting only vegetable consumption to undergo evaluation in a randomized study of adults attempting to lose weight."

#### **METHODS**

## 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A randomized controlled study design was used, with a 1:1 allocation ratio of intervention to wait-listed control (12-week delay)."

# 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

No changes were made after the study commenced.	

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study was short in duration, and the app did not undergo changes during this time. $ \\$							

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were overweight adults motivated to lose weight and eat healthier. Individuals were recruited from an ongoing 12-month weight-loss trial (n=609) based at Stanford University (parent trial), in which individuals were 18-50 years of age, had initial BMI=27-40, were non-diabetic and non-hypertensive, had no cancer or heart, renal, or liver disease, and lived in the geographical area surrounding Stanford. The added eligibility criterion for the current pilot study was ownership of an iPhone."

#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The added eligibility criterion for the current pilot study was ownership of an iPhone." Beyond ownership of an iPhone, no further computer/internet literacy eligibility criterion was used.

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Individuals were recruited from an ongoing 12-month weight-loss trial (n=609) based at Stanford University (parent trial)."

"During a pre-randomization orientation session taking place face-to-face, participants were instructed that the mobile app was intended to support them in increasing their vegetable consumption, and that it was ideally to be used for 1-2 minutes on a daily basis."

"Participants providing written consent were requested to complete a baseline questionnaire self-administered online."

"Participants randomized to the pilot study intervention condition completed a short online tutorial that described the mobile app and its use."

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"During a pre-randomization orientation session taking place face-to-face, participants were instructed that the mobile app was intended to support them in increasing their vegetable consumption, and that it was ideally to be used for 1-2 minutes on a daily basis. They were instructed to avoid using any other apps focused on vegetable consumption for the duration of the study. Participants providing written consent were requested to complete a baseline questionnaire self-administered online. All participants who completed the questionnaire were randomized."

## 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Individuals were recruited from an ongoing 12-month weight-loss trial (n=609) based at Stanford University (parent trial). ...The study was implemented during months 7-10 of the parent trial (in which participants were randomized to either a low-fat or a low-carbohydrate diet for 12 months and attended 22 evening classes with a health educator)."

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in webbased trials) or otherwise.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 4b-i? \*

"Outcome data were collected from both conditions using a questionnaire self-administered online 12 weeks post-randomization. ...To assess the primary outcome of daily vegetable consumption at baseline and 12 weeks post-randomization, an adapted version of the validated semi-quantitative Harvard Food Frequency Questionnaire (FFQ) was used."

#### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

#### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 5-i?

"Dustin Yoder and his team at Vendus Product Labs for their technical development of Vegethon."

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Formative research indicated that this target population desired a simple and efficient means of self-monitoring. ...To facilitate weight loss and weight maintenance in the context of the parent trial, the app focused on non-starchy vegetables with lower energy density and excluded starchy vegetables such as potatoes, corn, etc."

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 5-iii?

CONSORT-EHEALTH (V 1.0.1) - Submission/Publication Form
"The tutorial guided them through the process of downloading the app onto their iPhones from the iTunes App Store on December 4, 2014."
<b>5-iv) Quality assurance methods</b> Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.
1 2 3 4 5
subitem not at all important O O o essential
Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  Not applicable.
Not applicable.
5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-
capture video, and/or providing flowcharts of the algorithms used  Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video,
and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.
1 2 3 4 5
subitem not at all important O O O essential
Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Intervention screenshot are included in the archived version cited on
webcitation.org: "Vegethon iPhone App. Archived at: http://www.webcitation.org/6bejO73Gm2015; Available from:
https://itunes.apple.com/us/app/vegethon/id920899262?mt=8."

#### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <a href="webcitation.org">webcitation.org</a>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, the intervention URL is cited, along with the archived version on webcitation.org: "Vegethon iPhone App. Archived at: http://www.webcitation.org/6bejO73Gm2015; Available from: https://itunes.apple.com/us/app/vegethon/id920899262?mt=8."

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	0	$\bigcirc$	0	$\circ$	essentia

#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants randomized to the pilot study intervention condition completed a short online tutorial that described the mobile app and its use. The tutorial guided them through the process of downloading the app onto their iPhones from the iTunes App Store on December 4, 2014, creating a user account with their individual registration code, and setting their initial goals for quantity and variety of vegetables consumed."

## 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth

description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\circ$	$\bigcirc$	0	0	essential

#### Does your paper address subitem 5-viii? \*

"Vegethon [34] enabled self-monitoring of vegetable consumption and included a constellation of theory-driven features to maximize behavior change and sustain user engagement. Formative research indicated that this target population desired a simple and efficient means of selfmonitoring. Vegethon enabled swift vegetable logging by tapping on different vegetable icons (e.g., eggplant, arugula, etc.) to indicate the number of servings of each vegetable consumed. To facilitate weight loss and weight maintenance in the context of the parent trial, the app focused on non-starchy vegetables with lower energy density and excluded starchy vegetables such as potatoes, corn, etc. Tapping on each vegetable icon increased its quantity in increments of ½ servings. To reduce the cognitive load associated with self-monitoring, users were instructed by the app to estimate one vegetable serving as approximately the size of their fist. Users were able to select and modify goals for the quantity and variety (i.e., types) of their daily vegetable consumption on two sliding scales ranging from 1 to 10 servings and types, each anchored by an 'average' value of 2, 'recommended' value of 5, and 'superstar' value of 8. Default values [35] were set to the recommended 5 servings and 5 types of vegetables.

Several other theory-driven elements complemented the primary selfmonitoring feature. Seven ongoing challenges ranging from easy to difficult to perform were designed to reinforce the central target behaviors of vegetable consumption and logging (e.g., Breakfast Champ: Eat any vegetable before 11am). To build self-efficacy [36] and a sense of identity around vegetable eating, each participant was referred to as a Vegethoner, and challenges were given names that could be used to describe individual users (e.g., Variety King, Frequent Flyer). Elements of surprise and choice [37] were incorporated through surprise challenges delivered through push notifications to users every four days, which enabled the selection of one of two challenges, followed by the ability to accept (I'm in!) or decline (Not today). Shortterm progress monitoring was displayed with vertical bar graphs showing the current day's goals versus consumption. Long-term progress monitoring was displayed with horizontal bar graphs showing consumption for each of the previous seven days and seven weeks. Social comparison [38] was facilitated through a leaderboard in which users competed against "other Vegethoners" who were "most similar" to them. Feedback on the fulfillment of goals and challenges was reinforced through in-app notifications. Just-in-time prompts to log vegetables were delivered most evenings at 9pm through push notifications."

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5
subitem not at all important  $\bigcirc\bigcirc\bigcirc\bigcirc\bigcirc\bigcirc$  essential

#### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

information not in the ms	or briefly ex	olain wh	v the item is n	ot applicable/	relevant for v	vour studv
minoritia di ott filo titi di le filo	, or briefly ca	CPICITI WITE	,	ot applicable,	CICTAILLIOL	, our oraa,

"Participants were instructed that the mobile app was intended to support them in increasing their vegetable consumption, and that it was ideally to be used for 1-2 minutes on a daily basis. ...Participants in the intervention condition were instructed to use the app for a minimum of 6 weeks."

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"fu	lly-automated mo	obile app"		
				_

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-xi? \*

"Feedback on the fulfillment of goals and challenges was reinforced through in-app notifications. Just-in-time prompts to log vegetables were delivered most evenings at 9pm through push notifications."

#### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as standalone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was implemented during months 7-10 of the parent trial (in which participants were randomized to either a low-fat or a low-carbohydrate diet for 12 months and attended 22 evening classes with a health educator)."

# 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

#### "Vegetable consumption

To assess the primary outcome of daily vegetable consumption at baseline and 12 weeks post-randomization, an adapted version of the validated semi-quantitative Harvard Food Frequency Questionnaire (FFQ) was used [40, 41]. As with the Harvard FFQ, commonly used portion sizes for each vegetable (e.g., 1 onion or ½ cup of broccoli) were specified, and participants were asked to indicate how often, on average, during the past week, they had consumed each amount of food. All 28 questions on vegetable consumption comprising 33 vegetables were included from the Harvard FFQ, and eight response categories were possible, ranging from 0 to ≥6 times per day [42]. Daily vegetable intake was calculated for each participant following an established method [43, 44] in which the daily frequency of consumption for each vegetable item was multiplied by the number of servings represented by the specified portion size, based on USDA guidelines [45], and subsequently combined to yield total daily vegetable servings. Vegetable subgroups were defined a priori based on established criteria [46] adapted for specific use with the Harvard FFQ [47, 48]. Subgroups included green leafy vegetables (kale, mustard greens, chard, spinach, iceberg or head lettuce, romaine or leaf lettuce), cruciferous vegetables (broccoli, cauliflower, cabbage, coleslaw, Brussels sprouts), dark yellow vegetables (carrots, carrot juice, yams, sweet potatoes, dark orange (winter) squash), tomatoes (tomatoes, tomato juice, V-8 juice, tomato sauce, salsa, picante/taco sauce), beans/lentils (beans, lentils, tofu, soy burger or other soy protein), and other vegetables (eggplant, zucchini or other summer squash, celery, string beans, peas, lima beans, corn, mixed vegetables, stir-fry, vegetable soup, green/red peppers, onions). All vegetable subgroups apart from beans/lentils were assessed as secondary outcomes. Beans/lentils, which was not targeted by the intervention, was assessed as a control measure.

#### Intervention usability and satisfaction

Usability and satisfaction with the mobile app were assessed using a 21-item questionnaire, administered 12 weeks post randomization to the intervention condition only, and adapted from similar surveys used by King et al. to assess user acceptability of mHealth interventions [49]. Participants were asked to rate their level of agreement or disagreement with each statement on a 5-point Likert-type scale."

### 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

	CONSC	RT-EI	HEALTH (V 1.6.1) - Submission/Publica	ation Form
Though the survey's were not used in online studies many ti				
				<i>A</i>
6a-ii) Describe whether and defined/measured/monitore		se" (	including intensity of use	/dosage) was
Describe whether and how "use (logins, logfile analysis, etc.). U reported in any ehealth trial.				s defined/measured/monitored ess outcomes that should be
1	2 3	4	5	

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

"App usage was measured using inbuilt software tracking the date of app download, number of servings logged for each vegetable type, and time and date that logging occurred. Data was tracked for each participant using their individually assigned registration codes."

**6a-iii)** Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Participants were given the option to provide feedback to the researchers via e-mail and a form online. These methods of communication were rarely used and do not warrant reporting on in the manuscript.

### 6b) Any changes to trial outcomes after the trial

#### commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable	).		
			//

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

### 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A convenience sample drawn from the parent trial was used for this pilot study."	

## 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Not applicable.

# 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'a random, computer-generated allocation sequence to assign
participants to each condition"

# 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

"Participants were randomized and assigned prospectively via a balanced assignment approach designed to ensure balance across mobile intervention assignment, parent trial diet group (low-carbohydrate or low-fat), and parent trial health educator (of four possible health educators). Because this pilot study was conducted within an existing randomized parent trial, diet group and health educator could not be manipulated and were instead treated as nested strata. Pilot study participants were randomly assigned within these strata via a randomized, balanced block of size 4; subsequent participant assignments were selected via an a priori, deterministic procedure. This randomization assignment procedure was preferable to other randomization approaches because it ensured balance in all three variables at any given sample size of this pilot trial. Additionally, it was preferable to sequentially adjusted randomization procedures such as Efron's biased coin [39] because it allowed all assignments to be created prospectively."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants and researchers who performed data analysis were blinded to condition assignment. Randomization was performed by a researcher who had no contact with participants and used a random, computergenerated allocation sequence to assign participants to each condition."

# 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

"Randomization was performed by a researcher who had no contact with participants and used a random, computer-generated allocation sequence to assign participants to each condition. Enrollment and post-randomization communication with participants was subsequently performed by a research assistant who did not play a role in the data analysis."

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants and researchers who performed data analysis were blinded to condition assignment. ...All parent trial staff members, including the dietitians leading the health education classes, were blinded to condition assignment, and participants were instructed not to discuss the app with their health educator or with other participants."

### 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

information not in the ms, or briefly explain why the item is not applicable/re	levant for your study
"Participantswere blinded to condition assignment."	

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant.		
		/

# 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

"An analysis of covariance (ANCOVA) was used to assess differences between intervention and control conditions, with vegetable consumption as the dependent variable, condition assignment as the fixed factor, and baseline value of the dependent variable as a covariate. An intention-to-treat analysis was used such that baseline observations were carried forward when participants were lost to follow up. A sensitivity analysis with multiple imputations to account for missing data was also used. Five imputed datasets were created using the chained equations method and pooled estimates using Barnard-Rubin adjusted degrees of freedom [50, 51]. Descriptive statistics were used to analyze participant baseline characteristics and user acceptability of the mobile app. SPSS Statistics software (v22, IBM, New York) was used."

#### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"An intention-to-treat analysis was used such that baseline observations were carried forward when participants were lost to follow up."

# 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

#### Does your paper address CONSORT subitem 12b? \*

"A sensitivity analysis with multiple imputations to account for missing data was also used."

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

#### X26-i) Comment on ethics committee approval

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants provided written informed consent, and this research was approved by the Stanford University Human Subjects Committee."

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1 2 3 4 5
subitem not at all important \( \cap \cdot \

#### Does your paper address subitem X26-ii?

"During a pre-randomization orientation session taking place face-to-face, participants were instructed that the mobile app was intended to support them in increasing their vegetable consumption, and that it was ideally to be used for 1-2 minutes on a daily basis. They were instructed to avoid using any other apps focused on vegetable consumption for the duration of the study. Participants providing written consent..."

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



#### **RESULTS**

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

"17 completed a baseline questionnaire and were randomized and analyzed (intervention: 8; control: 9)"					
	7				

# 13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Among the 17 enrolled participants, 75% of the intervention condition
and 78% of the control condition completed the post questionnaire
administered 12 weeks post-randomization. As noted earlier, an intent-
to-treat approach was applied in analyzing the study data."

#### 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, this is included. "Figure 5. Frequency of vegetable logging among intervention condition, during 6-week intervention period"						

### 14a) Dates defining the periods of recruitment and

### follow-up

#### Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Enrollment began in October 2014, and the study ended in February 2015."	
	1

#### 14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.		
		1

### 14b) Why the trial ended or was stopped (early)

#### Does your paper address CONSORT subitem 14b? \*

Not applicable.		

## 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, this is included. "Table 1. Participant baseline characteristics (mean $\pm$ SD)"	

#### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\circ$	$\bigcirc$	0	$\bigcirc$	essential

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Demographics for gender, age, BMI, and race/ethnicity are presented in Table 1. "Table 1. Participant baseline characteristics (mean $\pm$ SD)"	

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the

intervention.		
	1 2 3 4 5	
subitem not at all im	nportant O O O o essential	
Copy and paste rele	ddress subitem 16-i? * vant sections from the manuscript (includes from your manuscript), or elaborate on the ms, or briefly explain why the item is not	this item by providing additional
	e reported throughout the results section, CONSORT flowchart.	in the

#### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1 2 3 4 5
subitem not at all important  $\bigcirc\bigcirc\bigcirc\bigcirc\bigcirc\bigcirc$  essential

#### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, primary analysis was intention-to-treat. "Using intent-to-treat analyses, daily vegetable consumption (primary outcome) was significantly greater in the mobile app intervention compared to control condition at the end of the 12-week pilot study (adjusted mean difference: 7.4 servings; 95% CI: 1.4, 13.5; p=0.02). A multiple imputation sensitivity analysis (MI) was performed and did not significantly alter these results (p=0.03)."

# 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, effect sizes and confidence intervals are included for primary and all secondary outcomes. "Using intent-to-treat analyses, daily vegetable consumption (primary outcome) was significantly greater in the mobile app intervention compared to control condition at the end of the 12-week pilot study (adjusted mean difference: 7.4 servings; 95% CI: 1.4, 13.5; p=0.02). ... Among secondary outcomes defined a priori, there was significantly greater consumption of green leafy vegetables (adjusted mean difference: 2.6 servings; 95% CI: 0.1, 5.0; p=0.04), cruciferous vegetables (1.6 servings; 95% CI: 0.1, 3.2; p=0.04), and dark yellow vegetables (0.8 servings; 95% CI: 0.3, 1.4; p=0.004) in the intervention versus control condition. There were also non-statistically significant trends towards greater consumption of tomatoes (0.3 servings; 95% CI: 0.0, 0.6; p=0.08) and other vegetables (1.7 servings; 95% CI: -0.9, 4.3; p=0.2) in the intervention condition. Consumption of beans, which were not targeted by the intervention, remained constant (-0.1 servings; 95% CI: -0.3, 0.1; p=0.4)."

#### 17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	$\bigcirc$	0	0	0	essentia

#### Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Among those in the intervention condition who used the app (5 of 8 participants), participants logged their vegetable consumption a mean of 0.7 (SD=0.9) times per day. ...There was a downward trend in frequency of logging behavior over time, from  $0.8 \pm 1.2$  times per day during week one to  $0.3 \pm 0.6$  times per day during week six (mean  $\pm$  SD). There was wide variation in logging frequency between individuals, ranging from  $1.2 \pm 1.1$  to  $0.3 \pm 0.6$  times per day (mean  $\pm$  SD)."

## 17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b?	? *	17	subitem	١,	ORT	NSC	C	address	r	paper	vour	Does
--	-----	----	---------	----	-----	-----	---	---------	---	-------	------	------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to
indicate direct quotes from your manuscript), or elaborate on this item by providing additional
information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.			
			/

# 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

#### Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.		

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 18-i?

This type of analysis was not undertaken.	
	 6

# 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

#### Does your paper address CONSORT subitem 19? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. No harms were reported to the investigators.	

#### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. No privacy breaches or technical problems were reported to the investigators.		
	/	

#### 19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	$\bigcirc$	0	$\bigcirc$	0	essential

Does your	paper	address	subitem	19-	ii?
-----------	-------	---------	---------	-----	-----

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.		
		1

#### DISCUSSION

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



#### Does your paper address subitem 22-i? \*

"This pilot study aimed to determine the initial efficacy and user acceptability of a mobile app intervention designed to increase vegetable consumption through the creative application of behavior change theory and techniques. Twelve-week testing indicated that it significantly increased consumption of vegetables, including green leafy vegetables, cruciferous vegetables, and dark yellow vegetables in the small sample being studied. The mobile app intervention achieved reasonably high rates of engagement and was found to be easy and enjoyable to use by the sample of participants. Vegetable logging increases observed at 9pm support the use of push notifications for increasing user engagement. High usage of serving increments "0.5" and "1.0" suggests that the availability of half-serving (vs. full-serving) increments is appropriate for the logging of individual vegetable types. Given the improved health outcomes associated with increases in vegetable consumption, this pilot study suggests the need for larger, longer-term studies of Vegethon and similar technologies among overweight adults and other suitable target groups."

### 22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The small sample size of this study offers only an imprecise estimate of the effect size for vegetable consumption and prevented analysis of potential mediators and moderators. A larger study is indicated to more precisely estimate differences in vegetable consumption and to assess mediators and moderators of observed changes in dietary behaviors. The 12-week duration of this pilot study provides an assessment only of short-term effects, and a longer trial is warranted to determine whether the observed effects are sustained over a longer period of time."

# 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

	1	2	3	4	5	
subitem not at all important	0	0	0	$\bigcirc$	0	essential

#### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"There were several methodological limitations to this pilot study. The participants were concurrently enrolled in a weight loss trial and were interested in helping shape the development of mobile technology. Generalizability of these findings to other samples that are not enrolled in a weight loss trial and that may not be as highly motivated is unknown. The loss of 4 participants to follow-up in this short study may have resulted from the high volume of time-intensive requirements (e.g., classes, blood draws, questionnaires, etc.) simultaneously required of participants by the parent trial. There were inherent limitations to the adapted Harvard Food Frequency Questionnaire measurement tool used, including reliance on self-report (as with most dietary studies of free-living participants). Despite the high test-retest reliability of the FFQ over time in the control condition and in measures not targeted by the intervention (e.g., bean intake), the observed effect size for the primary outcome was notably large. Although the hypothesis was supported, it is possible that a portion of the observed differences were due to the use of Vegethon causing participants to become more attuned to their vegetable consumption, more accurate reporters of their vegetable consumption, and/or more aware of the vegetables they consumed in other foods. The small sample size of this study offers only an imprecise estimate of the effect size for vegetable consumption and prevented analysis of potential mediators and moderators. A larger study is indicated to more precisely estimate differences in vegetable consumption and to assess mediators and moderators of observed changes in dietary behaviors. The 12-week duration of this pilot study provides an assessment only of short-term effects, and a longer trial is warranted to determine whether the observed effects are sustained over a longer period of time."

### 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study

results for other organization	ns					
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"These effects were observed among participants who already had a relatively high baseline vegetable consumption compared to the U.S. national average. ...Further studies are indicated to evaluate the effect of the app among participants outside of the context of a weight loss intervention who may respond to different types of motivation. ...Generalizability of these findings to other samples that are not enrolled in a weight loss trial and that may not be as highly motivated is unknown."

## 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	ı	_	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"...Further studies are indicated to evaluate the effect of the app among participants outside of the context of a weight loss intervention who may respond to different types of motivation. ...Generalizability of these findings to other samples that are not enrolled in a weight loss trial and that may not be as highly motivated is unknown."

#### OTHER INFORMATION

### 23) Registration number and name of trial registry

Does y	our/	paper	address	<b>CONSORT</b>	subitem	23?	*
--------	------	-------	---------	----------------	---------	-----	---

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Clinical Trial Registry: ClinicalTrials.gov Registration Number: NCT01826591"	
Negistration Number: NCT01020391	

## 24) Where the full trial protocol can be accessed, if available

#### Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.		
		1

# 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This research was supported by Award Number R01DK0091831 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), a Gates Cambridge Scholarship, and an unrestricted gift from the Nutrition Science Initiative (NuSI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or NIH."

### X27) Conflicts of Interest (not a CONSORT item)

Other:

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

identical with the developers/sponsors of the intervention.	ct from or
1 2 3 4 5	
subitem not at all important O O O essential	
Does your paper address subitem X27-i?	
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "lik indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your stream.	
"CONFLICTS OF INTEREST None declared."	
About the CONSORT EHEALTH checklist	
As a result of using this checklist, did you make changes in your manuscript? *	
yes, major changes	
o yes, minor changes	
○ no	
What were the most important changes you made as a result of using this checklist?	
Including app usage data in the abstract results section.	
How much time did you spend on going through the checklist INCLUDING making chayour manuscript *	nges in
1-2 hours	
As a result of using this checklist, do you think your manuscript has improved? *	
o yes	

Would you like to become involved in the CONSORT EHEALTH group?  This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
O yes
<ul> <li>o no</li> </ul>
Other:
Any other comments or questions on CONSORT EHEALTH
Any other comments of questions on CONSORT EFIEALTH
STOP - Save this form as PDF before you click submit  To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.
When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.
Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!
Final step: Click submit!
Click submit so we have your answers in our database!
Submit  Never submit passwords through Google Forms.
Powered by  This content is neither created nor endorsed by Google.  Report Abuse - Terms of Service - Additional Terms